Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.

Abstract

Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia. Rituximab, an anti-CD20 monoclonal antibody, is established as standard therapy for this unique low grade lymphoma, due to its effectiveness and safety as monotherapy, in combination with chemotherapy or other targeted therapies in WM. Newer monoclonal antibodies, targeting CD20 or other surface antigens, have shown to be effective in patients with WM. In the current review we attempt to provide an overview of the mechanisms of action of monoclonal antibodies and discuss clinical evidence that support their use in WM and their therapeutic potential.

• Authors: Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis
• Journal: Leukemia research reports (Leuk Res Rep) Vol. 17 Pg. 100324 ( 2022) ISSN: 2213-0489 [Print] England
• PMID: 35572915 (Publication Type: Journal Article)
• Copyright: © 2022 Published by Elsevier Ltd.